

BELGIAN HOSPITALS – SURVEILLANCE OF ANTIMICROBIAL CONSUMPTION (BEH-SAC)

Eline Vandael, Boudewijn Catry

Contact: eline.vandael@sciensano.be

Content

- Introduction and objectives
- Methodology
- National results
- Reports on Healthstat.be: demo
- Strengths and weaknesses
- Future plans
- Experiences from hospitals: Caroline Briquet (St. Luc Brussels) and Franky
 Buyle (UZ Gent)





Introduction

Anatomical Therapeutic Chemical (ATC) classification

- Active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties
- Five different levels

J	Anti-infectives for systemic use	1st level, anatomical main group				
J01	Antibacterials for systemic use	2nd level, therapeutic subgroup				
J01C	Beta-lactam antibacterials, penicillins	3rd level, pharmacological subgroup				
J01CA	Penicillins with extended spectrum	4th level, chemical subgroup				
J01CA04	Amoxicillin	5th level, chemical substance				





Introduction

Defined Daily Dose (DDD) =

the assumed average maintenance dose per day for a drug used for its main indication in adults (70 kg)

- Numerator for drug consumption
- International unit
- To assess trends in drug consumption and to perform comparisons between population groups
- Normally one DDD for each drug (per administration route)
- Systematic update by experts
- Disadvantages: not appropriate for children and patients with reduced drug excretion,
 not always in line with the actual doses in the hospitals





Introduction



ESAC-Net

- Europe-wide network
- Reporting for Belgium: 1x/year (July-August)
- Reimbursement data
- Overall AM consumption
- Hospitals vs community
- DDDs/1000 inhabitants/day
- Results publically available



Belgian Hospitals • Surveillance of Antimicrobial Consumption

- Belgian hospitals
- Reimbursement data
- Individual reports for each hospital + benchmarking
- DDDs/1000 patient days + DDDs/1000 admissions





Objectives

- To develop and offer a scientifically standardized methodology to Belgian hospital (acute and chronic care hospitals), to follow-up their antimicrobial consumption in a quantitative way through time.
- To give Belgian hospitals the opportunity to benchmark, based on their antimicrobial consumption, with similar hospitals.
- To provide recent national and regional data (with an acceptable delay in time) to be able to evaluate the antimicrobial consumption in Belgian hospitals.





Methodology

	ABUH → 2007	BeH-SAC 2018
Source of the data	Hospitals	RIZIV-INAMI Reimbursement data
Data collection	1x/year	2x/year
Feedback reports	NSIH-web	Healthdata



- ↓ workload for hospitals
- ↓ variation in data collection
- more detailed data
- improved reporting





Methodology


Year + trimester	2003-2017 (→ year data 2018 expected in Jan 2020)			
Numerator	Consumed units per drug, translated in DDDs			
ATC-codes	A07A = Intestinal anti-infectives J01 = Antibacterials for systemic use J02 + D01BA = Antimycotics and antifungals for systemic use P01AB = Nitroimidazole derivatives J04A = Drugs for treatment of tuberculosis J05 = Antivirals for systemic use (only starting from 2015)			
Denominators	Patient days + admissions			
Hospitals	Acute care, chronic care and psychiatric hospitals Identified based on the RIZIV/INAMI-number Benchmarking per: - Kind (acute, chronic, psychiatric) - Type (primary, secondary, tertiary, specialised) - Size (large, medium, small) - Region (Brussels, Flanders, Wallonia)			
Hospital units	Including internal medicine, surgery, pediatrics, neonatology, maternity, ICU, infectious diseases, burn unit, geriatrics, specialised/chronic care, (neuro)psychiatry, surgical day hospitalisations			

DDDs/1000 patient days

DDDs/1000 admissions



Overall antibiotic consumption (J01) – All units without psychiatry and day hospitalizations
All Belgian acute-care hospitals (n=101)





Median antibiotic use in 2017:

503.2 DDDs/1000 patient days → 2003-2017: +9.4%

3271.7 DDDs/1000 admissions → 2008-2017: -8.5%








Overall antibiotic consumption (J01) – All units without psychiatry and day hospitalizations

All Belgian acute-care hospitals (n=101)

Per type of hospital











Top 10 most used products in 2017










DEMO BEH-SAC REPORTS ON HEALTHSTAT



- National reports → publically available
- Hospital reports → login with e-ID





www.healthstat.be


















Access to the hospital reports

Step 1: Contact the RAE (Responsible Access Entity) of your hospital to activate your access to the BeH-SAC reports

→ Link to step by step instructions for the RAE on www.nsih.be

Step 2: login on <u>www.healthstat.be</u> with your electronic identity card to open the reports


→ user manual to getting started on Healthstat on www.nsih.be

In case of technical problems, please contact the support of Healthdata: support.healthdata@sciensano.be or 02 793 01 42.

If this is the first time that your hospital participates in this surveillance, contact Eline Vandael of Sciensano for further instructions (eline.vandael@sciensano.be or 02 642 50 26).















→ Starting point

Focus on the most used products








- Boxplot with range other hospitals
- Table: % parenteral use



- → Focus on different AM groups
 - Overall antibiotic (J01) and antimycotic use (J02)
 - Fluoroquinolones (J01MA)
 - Third-generation cephalosporines (J01DD)
 - Carbapenems (J01DH)
 - Penicillins in combination with enzym inhibitors (J01CR)
 - Glycopeptides (J01XA) and polymyxins (J01XB)
 - Broad-spectrum antibiotics (J01CR05, J01DD, J01DE, J01DF, J01DH, J01MA, J01XA, J01XB, J01XX08/09/11)
- → Focus on different hospital units
 - o ICU (490)
 - o Geriatrics (300)
 - Surgery (210)
 - o Internal medicine (220)

CAVE: denominator = patient days for analyses per unit




→ Check denominators


- Evolution with a line
- Evolution of denominators (second y-axis)





Current use of the reports










Strengths and weaknesses



Reuse of existing data	Delay in data (± 1 year), adjustments possible		
No registration load for hospitals	Non-reimbursed use not included		
Uniformity data collection	DDDs ↔ actual doses used		
Extended database	DDDs not appropriate for children		
Detailed data on different levels (national, regional, hospital, unit)	No duration of treatment available		
Interactive reporting (Healthstat.be) with benchmarking	Units not detailed enough for feedback to specific prescribers		
Hospital-specific indicators (DDDs/1000 patient days and DDDs/1000 admissions)	No link with indication		








Future plans

- New indicator:
 DDA = DDD adjusted for the Belgian setting
- Validation of high/low consumers outliers or other hospitals voluntering...
- Extra reports on Healthstat to identify outliers/high consumption
- New project AM-DIA (Antimicrobial Consumption data of Belgian Hospitals linked with Diagnoses)
 - → minimal hospital data linked with facturation data





Validation



Possible differences between databases:

- DDD calculation (version WHO), ATC codes
- Denominator
- Which units are included (classification RIZIV/INAMI)
- Which hospital sites are included
- BeH-SAC: only reimbursed consumption





Future plans

- New indicator:
 DDA = DDD adjusted for the Belgian setting
- Validation of high consumers/outliers or other hospitals voluntering...
- Extra reports on Healthstat to identify outliers/high consumption
- New project AM-DIA (Antimicrobial Consumption data of Belgian Hospitals linked with Diagnoses)
 - → minimal hospital data linked with facturation data





Help/support/feedback



eline.vandael@sciensano.be +32 2 642 50 26



Satisfaction survey NSIH surveillances

French: https://surveys.wiv-

isp.be/index.php/179586?lang=fr

Dutch: https://surveys.wiv-

isp.be/index.php/179586?lang=nl





www.nsih.be



Sciensano Volksgezondheid & Surveillance Zorginfecties & Antimicrobiële Resistentie (NSIH)



NSTH

- -Over
- -Aankondigingen
- -Symposium
- -Tevredenheidsenquête
- -Contact

Ziekenhuizen.

Infecties

- -Bloedstroominfecties
- -Clostridium difficile
- -Postoperatieve wondinfecties
- -Intensieve zorgen

Antimicrobiële resistentie

- -MRSA
- -MRGN
- -VRF
- -EARS-net BE

Andere

- -Gebruik van antimicrobiële middelen
- -Handnygiene
- -Kwaliteitsindicatoren
- -ECDC PPS
- -OST

NL | FR | EN Inleiding | Deelname | Download | Contact

Waakprogramma voor het systemisch en gastro-intestinaal gebruik van anti-infectieuze geneesmiddelen

BeH-SAC: Belgian Hospitals - Surveillance of Antimicrobial Consumption

Inleiding

Antimicrobiële resistentie leidt tot hogere morbiditeit en bijkomende gezondheidszorguitgaven.

Bijgevolg beval de Europese Ministerraad de Lidstaten in 2001 aan om het voorzichtig gebruik van antimicrobiële geneesmiddelen aan te moedigen. Dit werd in juni 2017 ook bevestigd in het nieuwe 'One Health Action Plan against Antimicrobial Resistance' van de Europese commissie. Het is in dit kader dat vanaf 01/07/2007 een antibioticabeleidsgroep wettelijk verplicht is in alle Belgische acute zorg ziekenhuizen en in de chronische ziekenhuizen met minstens 150 bedden.

De werkgroep ziekenhuisgeneeskunde van de Commissie voor de Coördinatie van het Antibioticabeleid (BAPCOC) volgt deze maatregel op en zorgt ervoor dat elk Belgisch ziekenhuis feedbackrapporten over zijn gebruik van antimicrobiële middelen kan ontvangen.

(EV_25072017)

- Protocol
- DDD/DDA list
- National report
- Instructions Healthstat

Acknowledgements

Participating hospitals

BAPCOC working group Hospital Medicine





NSIH-team, Nathalie Verhocht, Tadek Kryzwania

Healthdata: Thaddé Mahmourian, Juan Quesada, Kris Vranken, Gaëtan Muyldermans

Contact: eline.vandael@sciensano.be










Hospitals with high total antibiotic consumption over time

Hospital	2 0 0 3	2 0 0 4	2 0 0 5	2 0 0 6	2 0 0 7	2 0 0 8	2 0 0 9	2 0 1 0	2 0 1 1	2 0 1 2	2 0 1 3	2 0 1 4	2 0 1 5	2 0 1 6	2 0 1 7
1															
2															
3															
4															
5															
6															
7															
8															
9															
10															
11															

≥ 90 percentile per type of hospital DDDs/1000 patient days








Percentiles total antibiotic consumption (DDDs/1000 patient days) per type of hospital:

≤10	>10 - ≤25	>25 - ≤50	>50 - ≤75	>75 - <90	≥90

Distribution hospitals 2013-2017



- 5 years same percentile 4 years same percentile
- 3 years same percentile <3 years same percentile





Overall antibiotic consumption (J01) – All units without psychiatry and day hospitalizations ABUH versus BeH-SAC (database 2018)
Overlapping hospitals and years (2007-2014)

